tiprankstipranks
Trending News
More News >
Corcept Therapeutics’ Earnings Call Highlights Growth Amid Challenges
PremiumCompany AnnouncementsCorcept Therapeutics’ Earnings Call Highlights Growth Amid Challenges
1M ago
Corcept Therapeutics price target lowered to $135 from $150 at Truist
Premium
The Fly
Corcept Therapeutics price target lowered to $135 from $150 at Truist
1M ago
Corcept Therapeutics: Strong Growth Potential and Promising Pipeline Support Buy Rating
Premium
Ratings
Corcept Therapeutics: Strong Growth Potential and Promising Pipeline Support Buy Rating
1M ago
Corcept Therapeutics reports Q1 EPS 17c, consensus 14c
PremiumThe FlyCorcept Therapeutics reports Q1 EPS 17c, consensus 14c
1M ago
Corcept Therapeutics options imply 3.7% move in share price post-earnings
Premium
The Fly
Corcept Therapeutics options imply 3.7% move in share price post-earnings
1M ago
Positive Outlook for Corcept Therapeutics: Buy Rating Backed by Strong Financial Guidance and Pipeline Advancements
Premium
Ratings
Positive Outlook for Corcept Therapeutics: Buy Rating Backed by Strong Financial Guidance and Pipeline Advancements
1M ago
Corcept Therapeutics Stock (CORT) Rockets Up 100% After Groundbreaking Cancer Trial Success
PremiumMarket NewsCorcept Therapeutics Stock (CORT) Rockets Up 100% After Groundbreaking Cancer Trial Success
2M ago
Corcept Therapeutics price target raised to $142 from $130 at Canaccord
Premium
The Fly
Corcept Therapeutics price target raised to $142 from $130 at Canaccord
2M ago
Buy Recommendation for Corcept Therapeutics Driven by Promising Phase 3 ROSELLA Study Results and Market Expansion Potential
Premium
Ratings
Buy Recommendation for Corcept Therapeutics Driven by Promising Phase 3 ROSELLA Study Results and Market Expansion Potential
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100